Close×

With craft brewers now increasingly canning their products for protection, Barry-Wehmiller will bring its PneumaticScaleAngelus CB50F filler and seamer to stand C180 at AUSPACK 2019.

PSA has transferred its cam-driven multi-head rotary seamer technology to low-speed in-line applications, and the CB50F is the result. According to Gordon Wood of Barry-Wehmiller Australia, the machine features a compact footprint, jam-resistant mechanical design, and speeds of up to 50 cans per minute.

“Canning is rapidly becoming the package of choice,” said Wood. “Craft brewers are very attuned to taste, and understand their beer stays fresher and tastes better in a can.”

The CB50F is designed to minimise product loss and keep dissolved oxygen levels low in the can, says Barry-Wehmiller. The company claims the machine’s introduction of carbon dioxide at three points in the process consistently maintains oxygen levels below requirements.

“Light and oxygen are the two enemies of beer freshness,” said Wood. “Cans are impenetrable to light – and a well-seamed can provides the best seal possible.

“We aim to deliver high performance at a speed – and price point – that meets craft brewing needs,” said Wood. “The industry has responded well to the CB50F and, for those looking for the same performance in a one-hundred-can-per-minute system, we recently introduced the CB100F.”

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.